Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Venture Financing 17
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Partnerships 23
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
Licensing Agreements 38
MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38
Lundbeck Enters into Licensing Agreement with Vanderbilt University 39
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42
Equity Offering 43
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 45
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 46
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 47
Asset Transactions 49
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 49
Acquisition 51
Lundbeck Acquires Prexton Therapeutics 51
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 54
H. Lundbeck AS – Key Competitors 55
H. Lundbeck AS – Key Employees 56
H. Lundbeck AS – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 61
Financial Announcements 61
Nov 07, 2018: Lundbeck realized 12% growth in revenue and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised 61
Aug 08, 2018: Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS 62
May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS 76
Feb 07, 2018: Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit 77
Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017 78
Aug 09, 2017: Lundbeck reports 13% revenue growth and a doubling of EBIT in first half of 2017 79
May 10, 2017: Lundbeck: 2017 guidance raised based on strong revenue growth and improved profitability 86
Feb 08, 2017: Lundbeck continues to show solid revenue growth and strong improvement in profitability 87
Corporate Communications 88
Jul 02, 2018: H. Lundbeck Appoints Dr. Deborah Dunsire As President And CEO 88
Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company’s registered office 89
Oct 30, 2017: Changes to Lundbeck’s Executive Management 90
Sep 11, 2017: Changes in Executive Management in Lundbeck 91
Product News 92
Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) 92
Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 93
Apr 18, 2017: Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting 94
03/20/2018: Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech 95
Mar 03, 2017: Bioneer: In the Forefront of Developing New Human Cell Models for Neurodegenerative Diseases 96
Clinical Trials 97
Jun 25, 2018: Lundbeck starts clinical development of potential new treatment of Parkinson’s disease 97
Jul 10, 2017: Parkinson’s disease: Prexton announces initiation of phase II clinical testing 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
H. Lundbeck AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 15
Naurex Raises USD80 Million in Series C Venture Financing 17
Naurex Raises US$25 Million In Venture Financing 19
Naurex Raises US$38 Million In Series B Financing 21
Confo Therapeutics Enters into Agreement with H. Lundbeck 23
Cerveau Technologies Enters into Research Agreement with Lundbeck 24
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 25
Lundbeck Enters into Research Agreement with ImmunoBrain Checkpoint 26
H. Lundbeck Enters into Agreement with IBM Watson Health 27
Circuit Therapeutics Enters into Research Agreement with H. Lundbeck 28
Ossianix Expands and Extends Research Agreement with Lundbeck 29
Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 30
Ossianix Enters Into Co-Development Agreement With Lundbeck 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 35
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics 36
Lundbeck Plans To Enters Into Co-Development Agreement For Treatment Of Alzheimer’s Disease 37
MindImmune Therapeutics Enters into Licensing Agreement with Lundbeck 38
Lundbeck Enters into Licensing Agreement with Vanderbilt University 39
Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 40
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 41
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 42
H. Lundbeck Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 43
H. Lundbeck to Raise USD3.2 Million in Private Placement of Shares upon Exercise of Warrants 44
Chelsea Therapeutics Completes Public Offering Of Shares For US$23 Million 45
Chelsea Therapeutics Files Shelf Registration Statement For Public Offering Of US$100 Million 46
Chelsea Therapeutics Completes Public Offering Of Common Stock For US$24 Million 47
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 49
Lundbeck Acquires Prexton Therapeutics 51
H. Lundbeck Completes Acquisition of Chelsea Therapeutics for USD658 Million 52
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 54
H. Lundbeck AS, Key Competitors 55
H. Lundbeck AS, Key Employees 56
H. Lundbeck AS, Subsidiaries 57
List of Figures
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
H. Lundbeck AS, Medical Devices Deals, 2012 to YTD 2018 11